# Clinical Studies / Etudes Cliniques

**Clinical Studies / Etudes Cliniques**

**Ophthalmic Manifestations in Patients with Intracranial Tumours / Manifestations Ophtalmiques Lors de Tumeurs Intracrâniennes**

ONAKPOYA Oluwatoyin Helen

KOMOLAFE Edward Oluwole

AKINTOMIDE Folasade

AJITE Kayode

KOMOLAFE Morenikeji Adeyoyin

ADEOLU Augustine Abiodun

OLATEJU Samuel Oluremi

ADEOYE Adenike Odunmorayo

ADEGBEHINGBE Bernice Olukemi

1. Neurosurgical Unit, Department of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, NIGERIA

2. Ophthalmology Units, Department of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria

3. Neurology unit, Department of Medicine, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria

E-Mail Contact - ONAKPOYA Oluwatoyin Helen: ufuoma (at) oauife (dot) edu.ng

**Keywords:** Manifestation, Intracranial Tumours, Blindness, Ophthalmic, Nigeria

---

**Resume**

**Introduction**

L'étude a pour but d'apprécier les manifestations ophtalmologiques des patients présentant des tumeurs cérébrales au Nigéria dans un hôpital tertiaire.

**Méthode**

Il s'agit d'une étude rétrospective avec une revue des tumeurs cérébrales dans le Neurosurgical Unit of Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife de janvier 2003 à décembre 2007. L'analyse des données, diagnostique, acuité visuelle, et prise en charge, ont été analysées selon la fréquence en utilisant avec la version 1 11 SPCS. L'acuité visuelle a été classifiée selon celle de l'OMS.

**Résultat**

Sur un total de 94 patients, 88 patients ont été revus. Il s'agissait de 53 patients de sexe masculin et 35 de sexe féminin. La moyenne d'âge était de 36.2 plus ou moins 20 ans. 14 patients ont été pris en charge par les ophtalmologistes. La répartition des tumeurs était la suivante: méningiomes, 36,4 %, craniopharyngiomes, 13,6 % et gliomes, 9,1 %. 67,9 % des patients se plaignaient de troubles visuels à l'admission dont 46,6 % avec une baisse importante et 12,5 % une vision double. Il a été objectivé une atrophie optique dans 23,9 %. 46 malades (52 %) étaient aveugles et 14 (16 %) avaient un trouble visuel important.

**Conclusion**

Les troubles visuels sont des manifestations cliniques fréquentes de présentation des tumeurs cérébrales. Une information médicale précoce est requise.
SUMMARY

Background
This study was aimed at determining the ophthalmic manifestations of patients presenting with brain tumours in a Nigerian tertiary hospital.

Method
A retrospective crossectional review of patients with brain tumors in the Neurosurgical Unit of Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife from January 2003 to December 2007 was conducted. Data on biodata, source of referral, diagnosis, visual acuity at presentation and management were recorded and analyzed for simple frequency using the SPSS version 11. Visual acuity was classified using the WHO classification for presenting acuity in the better eye.

Results
Out of a total of 94 patients, 88 with complete information were reviewed. There were 53 [60.2%] males and 35 [39.8%] females; the mean age was 36.2±20 years. Fourteen [15.9%] patients were referred by Ophthalmologists. Meningiomas(36.4%), craniopharyngioma(13.6%) and gliomas(9.1%) were the most common brain tumours encountered. Fifty nine(67.9%) had visual complains at presentation; poor vision (46.6%) and double vision (12.5%) were the most common ocular symptoms while opticatrophy was the commonest ocular sign (23.9%). 46 (52%) %) were blind while 14(16%) had visual impairment. Patients with visual impairment and blindness were more likely to have visual complains at presentation (88.3%) compared with 50% amongst patients with normal vision (P=0.003).

Conclusion
Ophthalmic signs and symptoms form a major part of presentation in patients with intracranial tumours. Health education and complete ophthalmic evaluation is essential in patients with brain tumours.

INTRODUCTION
Primary brain tumours constitute a major reason for seeking neurological consultations worldwide1-3. The location and type of tumour influences the clinical presentation and the management option. The clinical features in patients with brain tumours may be caused by their mass or irritating effect, influence on hormone secretion/depression or their mass related pressure effect on the surrounding structures or development of hydrocephalus4,5 . Intracranial tumours present with ophthalmic abnormalities; these abnormalities could result from their effect on the visual pathway, ocular nerves and oribto-ocular tissues 3,5-11. Ophthalmic signs and symptoms in brain tumors include visual loss, double vision, nerve palsys, pupillary abnormalities, proptosis and optic nerve head defects; their presentation being largely affected by the type, location and size of the of tumors 7. Neuro-ophthalmic involvement of 46.8% - 88.6% have been reported in different series of intracranial tumours 3,7,10,11. Visual symptoms and signs form major aspects of presentation in certain types of brain tumours and may be of immense help in making appropriate and early diagnosis when initial signs are unspecific 7,8,10,12.

Intracranial tumors affect almost any tissue in the brain leading to different spectrum of brain tumours. In a study of patients with brain tumours in New York, Snyder at al reported malignant astrocytoma as the most frequent tumor 14. Pisarev et al reported gliomas as the commonest brain tumor in the Volgograd region where it represented 51.9% of all intracranial tumors13; while in Iran and Thailand, meningiomas were the commonest representing 26% and 45% of all brain tumors respectively 1,10. Patients from developing countries tend to present late with larger masses and this may affect the prevalence and pattern of ophthalmic manifestations at presentation. The purpose of this paper is to document the ophthalmic manifestations of patients presenting with intracranial tumours in a Nigerian tertiary neurosurgical unit.

METHODOLOGY
Setting
The neurosurgical unit of the Obafemi Awolowo University Teaching Hospital, (OAUTHC) Ile-Ife is a referral unit for patients with neurosurgery diseases. The unit comanages patients with the Ophthalmology Unit and Neurology Unit of the same institution as required. It provides neurosurgical care for Osun, Ondo, Ekiti, Edo and Delta States of southwestern and south southern Nigeria being the only centre with such facility (Fig I). The unit also treats self presenting patients to the surgical out-patient clinic as well as the accident and emergency department of the hospital.

http://ajns.paans.org
Study design
A 5-year retrospective descriptive review of in-patients managed for intracranial tumors from January 2003 to December 2007 was conducted. Patients with intracranial space occupying inflammatory or vascular lesions were excluded. Preoperative diagnosis was made based on the clinical presentation and radiological investigations. Histological diagnosis was made postoperatively. Presenting visual acuity was recorded using the Snellen’s chart or illiterate E chart; this was further classified using the World Health Organizations classification into normal, visual impairment, severe visual impairment or blindness; infants were classified as blind or believed not to be blind depending on their ability to perceive/follow light and reach out for objects presented. The presence or otherwise of visual complains was noted at presentation as well as the duration of symptoms prior to presentation. Diagnosis was made following clinical examinations and radiological and histological examinations. In patients who did not have surgical treatment, diagnosis was based on clinical and radiological examinations. With the aide of a pre-designed questionnaire, the biodata, source of referral, diagnosis, tumour location, presenting visual acuity, eye complains and radiological investigations were recorded. Data thus collected were analyzed and presented as frequency tables and percentages for discussion using SPSS version 11. Comparison between variable was carried out with Chi square and statistical significance inferred at p<0.005.

RESULTS
Out of a total of 94 patients managed for intracranial tumours, 88 with complete records were analyzed.

Socio-demographic distribution
There were 53 [60.2%] males and 35 [39.8%] females with a male to female ratio of 1.5:1. The mean age was 36.2±20.1 years; 43.2% were within the 36-55 years age group while 19.3% belonged to the pediatric age group (≤ 15 years). Male preponderance was noted across all age groups except in children aged five years and below in whom a male to female ratio of 1:1.8 was recorded. Figure I shows the age and sex distribution of patients managed for brain tumours. Most of the patients 36 (40.9%) resided within the state of location of the neurosurgical facility (Osun State) or 41 (46.6%) within the same zone (southwest). [Table I]

Pattern of referral
Referral was mainly from private hospitals 36(40.9%) while referrals from public hospitals were largely from the general outpatient department and emergency rooms of within the same institution 24(27.4%). [Table I] Patients had sought previous neurologist 9(10.2%), ophthalmologist 14 (15.9%) and paediatrician 10 (10.4%) consultation before presentation. Duration of symptoms prior to neurosurgical attention ranged from 1 to 484 weeks with a mean of 63.1±107.8 weeks. (52.7%) presented for neurosurgical care more than twelve weeks from the onset of symptoms related to the intracranial tumour. [Table I]

Ocular status
59 (67%) had eye complains at presentation while 29(33%) made no complains referable to the eyes. Poor vision (46.6%) and double vision (12.5%) were the commonest ocular symptoms. Ocular findings were normal in 45 (51.3%) patients while optic atrophy was the commonest ocular sign (23.9%). [Table III] Ocular nerve palsy was present in 16(18.2%) out of which 9(56.3%) involved the sixth nerve, 5(31.3%) the third nerve and 2(12.4%) were multiple nerve palsies. Unilateral blindness was present in 3(3.4%) and unilateral visual impairment in 6(6.8%); bilateral blindness was present at presentation in 46 (52%) [Figure II]. Patients with visual impairment and blindness were more likely to have eye complains at presentation (88.3%) compared with 50% amongst patients with normal vision using the WHO classification (P=0.003).

Spectrum of intracranial tumours
Radiological investigations conducted were cranial CT scan in 84 [95.5%], MRI in 1[1.1%], and skull X-rays in 3[3.4%]. Supra-tentorial tumours were more common 77 [87.5%]. Meningiomas(36.4%), Craniopharyngioma(13.6%) and gliomas(9.1%) were the commonest brain tumours encountered (Table III).

DISCUSSION
The mean age of 36.2 years of patients with brain tumour recorded in this study is younger than the 42.8 years and 50.76 years reported in New York and Romania respectively; it however compares favourably with the 33.9 and 37 years reported from Iran and Kenya1,7,14,15. This is obviously a disease affecting mainly
young adults and middle aged- the economically and physically active subset in any society. Children
constituted 19.3% of the patients with brain tumours in this study similar to the 20.1% reported by Mehrazin et
al1; brain tumours are the most common solid tumour entity in childhood.13 The male preponderance may be
related to hospital biased design as male utilization of health care facility in sub-saharan African is generally
reported to be higher than females. The reason for the female predominance in the pediatric age group may
require further epidemiological studies as the reason for this is not known. The signs and symptoms of
intracranial tumours are usually none specific and may be slowly evolving; this may be responsible for the
previous consultations before final referral to the neurosurgical unit. Moreover, Cranial Tomography scan is
not commonly available or affordable by many patients in our environment hence the delay in appropriate
diagnosis and referral.

The location, size and involvement of the visual pathway and ocular nerves determine to a large extent the
degree of involvement of the eyes in brain tumours. In this study, about two-thirds (67%) of patients with
intracranial tumours had ophthalmic symptoms at presentation. This is similar to the slightly higher value of
72% reported by Marco et al in Kenya where poor referral network and poverty leading to delayed
presentation for neurosurgical care were implicated 15. Anderson et al reported a much lower rate of 30%
among patients with meningiomas 16. Poor vision as the most common ophthalmic symptom in this series is
similar to previous reports; however, while this symptom was reported in 52% of our patients, much higher
frequency of 88.6% and 86% were reported 10,11. The difference may be related to the difference in the
pattern of brain tumours studied; meningiomas and parasellar tumors (pituitary adenoma and cranipharyngioma) constituted 84.6% of all brain tumours studied as compared to 55.6% in the present
study. The anatomical location of these tumours predisposes them to more frequent mass-compression
effect on the optic nerve, optic chiasma and optic tract; hence more frequent involvement of the vision.
Ocular cranial nerve involvement is responsible for double vision which was found in 12.5% of patients
studied; this is within range although slightly higher than the 10% reported in Kenya 15. The frequency of
double vision as a symptom may not represent all the cases of ocular deviations and cranial nerve
involvement as patients with severe visual impairment and blindness may not experience double vision.
Moreover, young children are not articulate enough to complain of double vision ref. Although 18.2% of the
patients with intracranial tumours on examination had ocular deviation due to involvement of ocular cranial
nerves, only 12.5% complained of double vision. Ocular nerves can be affected by intracranial tumour due to
their mass effect or infiltration by the tumour. Although, the third cranial nerve is the commonest palsy
accompanying pituitary tumours, the sixth cranial nerve is frequently affected by the resultant raised
intracranial pressure from intracranial tumours; this is a possible explanation for its commoner occurrence
compared to the third and fourth nerves in this study.

Over half of our patients were blind at presentation for neurosurgical care; this compares favourable with the
59% of blindness recorded in Thailand amongst patients with intracranial tumours 10. In a similar study in
New York, total percentage of visual deficit reported was 19.8%. The higher percentage of blindness in
developing countries as opposed to developed country may be related to late presentation for neurosurgical
care with larger tumour and in advanced disease in the former. During the period of study, about 59.1% of the
patients were referred from outside the state of location of the neurosurgical centre. In a developing country
setting like ours, the adverse effects of poor socio-economic status on health care viz-a-viz utilization and
late presentation comes to play more when health care facility is located far from the patient.

Optic nerve head changes, that is, optic atrophy and papilloedema were present in 44.4% patients with brain
tumor in this study. The importance of ophthalmoscopy as part of required neurological examination for early
diagnosis of intracranial space occupying lesions is further justified. Papilloedema was reported in 27.7% and
46.8% of patients with intracranial tumours in New York and Romania respectively 7,14. Anteriorly located
intracranial tumours have a higher propensity to compress the optic pathway and hence present earlier with
optic nerve compressive changes seen at ophthalmoscopic examinations 15. Visual field defects were the
commonest ophthalmic sign and were seen in 80.5% of patients with intracranial tumour 12 while Marco et al
also reported non-specific field pattern (34%) as the most common visual field changes in patients with
intracranial tumours 15. In the present study, this sign was not objectively assessed as visual field analyzer
was not available in the study centre and its immediate environs.

In conclusion, ophthalmic clinical features form a major part of presentation of patients with intracranial
tumours. Complete neuro-ophthalmic evaluation seeking for the signs and symptoms enumerated is
essential for diagnosis.

http://ajns.paans.org
### Table I: Characteristic of patients with brain tumours

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Domicile</strong></td>
<td></td>
</tr>
<tr>
<td>Osun</td>
<td>36 (40.9)</td>
</tr>
<tr>
<td>Southwest (outside Osun State)</td>
<td>41 (46.6)</td>
</tr>
<tr>
<td>South-south</td>
<td>8 (9.1)</td>
</tr>
<tr>
<td>North</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>88 (100)</strong></td>
</tr>
<tr>
<td><strong>Source of referral</strong></td>
<td></td>
</tr>
<tr>
<td>General outpatient department</td>
<td>16 (18.3)</td>
</tr>
<tr>
<td>Tertiary Hospitals</td>
<td>9 (10.2)</td>
</tr>
<tr>
<td>Secondary Hospitals</td>
<td>19 (21.6)</td>
</tr>
<tr>
<td>Private Hospitals</td>
<td>36 (40.9)</td>
</tr>
<tr>
<td>Self (casualty/emergency room)</td>
<td>8 (9.1)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>88 (100)</strong></td>
</tr>
<tr>
<td><strong>Duration of Symptoms before Presentation</strong></td>
<td></td>
</tr>
<tr>
<td>1-6 weeks</td>
<td>17 (18.9)</td>
</tr>
<tr>
<td>7-12 weeks</td>
<td>25 (28.4)</td>
</tr>
<tr>
<td>13-17 weeks</td>
<td>6 (6.8)</td>
</tr>
<tr>
<td>&gt;= 18 weeks</td>
<td>40 (45.9)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>88 (100)</strong></td>
</tr>
</tbody>
</table>

### Table II: Eye symptoms and signs in patients with intracranial tumours

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Frequency (%)</th>
<th>Signs</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor vision</td>
<td>41 (46.6)</td>
<td>Optic atrophy</td>
<td>21 (23.9)</td>
</tr>
<tr>
<td>Double vision</td>
<td>11 (12.5)</td>
<td>Anisocoria</td>
<td>20 (22.7)</td>
</tr>
<tr>
<td>Eye ache</td>
<td>3 (3.4)</td>
<td>Papilloedema</td>
<td>18 (20.5)</td>
</tr>
<tr>
<td>Proptosis</td>
<td>2 (2.3)</td>
<td>Ocular nerve palsy</td>
<td>16 (18.2)</td>
</tr>
<tr>
<td>Drooping lid</td>
<td>2 (2.3)</td>
<td>Pupillary reaction defect</td>
<td>12 (13.6)</td>
</tr>
<tr>
<td>Eye deviation</td>
<td>1 (1.1)</td>
<td>Proptosis</td>
<td>10 (11.4)</td>
</tr>
<tr>
<td>Redness</td>
<td>1 (1.1)</td>
<td>Ptosis</td>
<td>5 (5.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Foster Kennedy Syndrome</td>
<td>2 (2.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nystagmus</td>
<td>1 (1.1)</td>
</tr>
</tbody>
</table>

# - multiple signs were present in some patients
### Table III: Spectrum of intracranial tumours

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meningioma</td>
<td>32(36.4)</td>
</tr>
<tr>
<td>Craniopharyngioma</td>
<td>12(13.6)</td>
</tr>
<tr>
<td>Glioma</td>
<td>8(9.1)</td>
</tr>
<tr>
<td>Pituitary adenoma</td>
<td>5(5.7)</td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>5(5.7)</td>
</tr>
<tr>
<td>Pinealoma</td>
<td>4(4.5)</td>
</tr>
<tr>
<td>Cerebellopontine angle tumor</td>
<td>3(3.4)</td>
</tr>
<tr>
<td>Cerebellar tumour</td>
<td>3(3.4)</td>
</tr>
<tr>
<td>Frontal lobe tumour</td>
<td>3(3.4)</td>
</tr>
<tr>
<td>Thalamic tumour</td>
<td>2(2.3)</td>
</tr>
<tr>
<td>Astrocytoma</td>
<td>2(2.3)</td>
</tr>
<tr>
<td>Soft tissue sarcoma</td>
<td>2(2.3)</td>
</tr>
<tr>
<td>Others</td>
<td>6(6.8)</td>
</tr>
<tr>
<td>Total</td>
<td>88(100)</td>
</tr>
</tbody>
</table>

**Figure 1**

Age and Sex Distribution of Patients with Brain Tumours

[http://ajns.paans.org](http://ajns.paans.org)
Figure 2
Visual status of patients with intracranial tumours
REFERENCES